Saturday, December 3, 2022

561.316.3330

Biotechnology News Magazine

Dr Paul Brooks Appointed Chief Business Officer of CN Bio

Latest Posts

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treatment of several hematologic cancers, including in combination with azacytidine for elderly patients with AML unable to tolerate the standard of care.

Acer Therapeutics Announces $1.5M Private Placement

The proceeds from the private placement will be used by Acer Therapeutics for working capital and general corporate purposes and, together with Acer’s existing cash and cash equivalents, are expected to be sufficient to fund the Company’s anticipated operating and capital requirements through the fourth quarter of 2022.

AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “The selection of ACI-35.030 for further development is a significant step for this collaboration. Early clinical testing showed that ACI-35.030 was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and enriched paired helical filaments (ePHF) species, both of which are closely implicated in Alzheimer’s disease (AD).

TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors

The planned clinical trial is to evaluate TransCode’s lead therapeutic candidate, TTX-MC138, in cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode Therapeutics believes that TTX-MC138 could be used as a treatment for many of these cancers.

Dr Paul Brooks will be responsible for shaping the company’s commercial business strategy and leading the expansion of its global commercial organization.

Dr Paul Brooks is an experienced C-suite level executive with over 25 years in the life science industry building businesses and leading high-performance research, product development, marketing, and sales teams to develop and commercialize new biotechnology technologies. He joins CN Bio from Horizon Discovery, a PerkinElmer Company, where he led the strategic and operational transformation of its business units as Head of Business Operations & Managing Director, driving revenue growth across its service, product, and licensing businesses. P

He held various management roles at Sigma-Aldrich; acquired by Merck Group in 2015 to form MilliporeSigma, where he joined the leadership team as Head of Discovery Research Services & General Manager and led the successful formation of its global-leading product and service portfolio for drug discovery research. In 2016, Dr Paul Brooks relocated back to the UK as Chief Commercial Officer & Executive Director and Board member at Oxford Genetics, driving the rapid scaling of the synthetic biology start-up company and commercialization of its technology.

Paul has a BSc in Biochemistry from the University of Wales, a Ph.D. in Molecular Biology from the University of Manchester Institute of Science and Technology, and an MBA from the University of Nottingham Business School.

Dr. David Hughes, Chief Executive Officer, CN Bio, said: “Paul not only has experience across a range of large, globally-recognized life sciences businesses but also driving growth within smaller teams. He has a very strong track record and is well placed to help us grow commercially, moving us forward with our organizational strategy and goals. We are proud to have him joining the team and look forward to working together, enabling us to drive innovation in the sector by bringing more products to market.”

Dr. Paul Brooks, Chief Business Officer, CN Bio, commented: “The potential within the Organ-on-a-Chip space to revolutionize drug discovery is remarkable. CN Bio is demonstrating these possibilities with its next-generation PhysioMimix micro physiological technology, not only to accelerate the accurate and reliable development of new therapeutics but also critically reducing researchers’ dependence on animal models. It’s an exciting time to be joining CN Bio at an important inflection point in its history, and I’m eager to work alongside the team to help realize this potential.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine